The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described.

TREATMENT OF TNFAlpha RELATED DISORDERS

Disclosed is an isolated human anti-human TNF-alpha antibody comprising: - a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 (QRYNRAPYT/A), a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 (AASTLQS), and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 (RASQGIRNYLA); and - a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4 (VSYLSTASSLDY/N), a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6 (AITWNSGHIDYADSVEG), and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8 (DYAMH), wherein the antibody comprises an IgG1 heavy chain constant region and a kappa light chain constant region.

Human antibodies that bind human TNFa

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

Protein formulations and methods of making same

The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.

Crystalline anti-htnfalpha antibodies

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Formulation of human antibodies for treating tnf-alpha associated disorders

A liquid aqueous pharaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Pharmaceutical anti-tnf-alpha antibody formulation

Pharmezeutische anti-tnf-alpha antikörper formulierung

PROBLEM TO BE SOLVED: To provide a stable and long-storage aqueous pharmaceutical preparation containing a human antibody for treating of a tumor necrosis factor α related disorder.SOLUTION: The aqueous preparation contains: the antibody for treatment in a concentration of more than about 45 mg/ml; a full-dose surfactant such as a polyol and polysorbate 80 as typified by mannitol; and a buffer system including a citric acid having pH about 4-8 and/or phosphate.

Formulation of human antibody for treating of disease related to tnf-alpha

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

Michael Dickes

Author Tools

Chat about Author

Papers

Formulation of human antibodies for treating tnf-alpha associated disorders

Pharmaceutical anti-tnf-alpha antibody formulation

Pharmezeutische anti-tnf-alpha antikörper formulierung

Formulation of human antibody for treating of disease related to tnf-alpha